ARGX
argenx SE
NASDAQ · Healthcare · Biotechnology · NL
$1,033.15
−1.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.8B | 4.2B | 2.2B | 1.2B | 410.7M |
| Cost of Revenue | 810.7M | 450.7M | 227.3M | 117.8M | 29.4M |
| Gross Profit | 6.9B | 3.7B | 2.0B | 1.1B | 381.3M |
| Operating Expenses | |||||
| R&D Expense | 1.6B | 1.4B | 983.4M | 859.5M | 663.4M |
| SG&A Expense | 1.7B | 1.4B | 1.1B | 709.5M | 469.9M |
| General & Admin Expense | 532.5M | 930.8M | 748.4M | 507.4M | 354.0M |
| Selling & Marketing Expense | 240.2M | 429.2M | 307.0M | 202.1M | 116.0M |
| Other Expenses | 1.6B | (75.9M) | (54.2M) | (35.5M) | (31.6M) |
| Total Operating Expenses | 4.9B | 2.6B | 2.0B | 1.5B | 1.1B |
| Cost and Expenses | 5.7B | 3.1B | 2.2B | 1.7B | 1.1B |
| Operating Income (EBIT) | 2.0B | 1.1B | (21.7M) | (425.0M) | (720.3M) |
| Non-Operating | |||||
| Interest Income | 211.6M | 163.1M | 138.5M | 93.0M | 24.7M |
| Interest Expense | 5.3M | 4.1M | 2.2M | 904.0K | 2.2M |
| Net Interest Income | 206.3M | 159.0M | 136.3M | 92.1M | 22.5M |
| Other Non-Op Income/Expense | 397.2M | 224.0M | 106.8M | 120.6M | (9.0M) |
| Non-Operating Income (excl Interest) | (290.3M) | (228.1M) | (109.3M) | (121.5M) | 6.8M |
| EBT (Pre-Tax Income) | 2.4B | 1.3B | 85.2M | (304.5M) | (729.3M) |
| Income Tax Expense | 138.6M | (13.4M) | (747.9M) | (9.4M) | (19.7M) |
| Bottom Line | |||||
| Net Income | 2.3B | 1.3B | 833.0M | (295.1M) | (709.6M) |
| Earnings from Cont. Ops | 2.3B | 1.3B | 833.0M | (295.1M) | (709.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.3B | 1.3B | 831.6M | (295.1M) | (709.6M) |
| Per Share | |||||
| Basic EPS | $37.37 | $21.14 | $13.92 | ($5.16) | ($13.05) |
| Diluted EPS | $35.19 | $19.63 | $12.78 | ($5.16) | ($13.05) |
| Revenue Per Share | $124.79 | $67.76 | $36.59 | $21.45 | $7.55 |
| Shares | |||||
| Basic Shares Outstanding | 62.2M | 61.3M | 59.9M | 57.2M | 54.4M |
| Diluted Shares Outstanding | 64.4M | 66.0M | 65.2M | 57.2M | 54.4M |
| Profitability Metrics | |||||
| EBITDA | 2.4B | 1.3B | 105.2M | (192.3M) | (622.8M) |
| D&A | 31.8M | 28.1M | 17.5M | 111.5M | 104.3M |
| EBIT | 2.3B | 1.3B | 87.6M | (303.6M) | (727.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026